Bio Green Med Solution

Cyclacel Pharmaceuticals, Inc., founded in 1997 by David P. Lane, PhD, is a biotechnology firm based in Berkeley Heights, New Jersey. The company focuses on the research and development of therapeutics for cancer and other serious diseases. Cyclacel's core mission is to harness cell cycle biology to develop innovative cancer medicines. Their product pipeline includes Fadraciclib and CYC140, targeting oncology and hematology indications. The company operates as a public entity traded on Nasdaq under the ticker CYCC.

Cyclacel has achieved significant milestones in its field, including the development of novel drug candidates that leverage cell cycle, transcriptional regulation, epigenetics, and mitosis biology. Under the leadership of CEO Spiro Rombotis, the company has made strides in clinical-stage biopharmaceutical advancements. Notable key people include Paul McBarron, EVP of finance and COO, and Mark Kirschbaum, MD, CMO. Cyclacel reported a net income of $19.1 million in 2021 and continues to impact the biotechnology industry with its pioneering approach to cancer treatment.